Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05238675
Registration number
NCT05238675
Ethics application status
Date submitted
3/02/2022
Date registered
14/02/2022
Date last updated
11/06/2024
Titles & IDs
Public title
A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis
Query!
Scientific title
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study Evaluating Efficacy, Safety and Tolerability of BI 1291583 qd Over at Least 24 Weeks in Patients With Bronchiectasis (AirleafTM)
Query!
Secondary ID [1]
0
0
2021-003304-41
Query!
Secondary ID [2]
0
0
1397-0012
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Bronchiectasis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BI 1291583
Treatment: Drugs - Placebo
Experimental: BI 1291583: Low dose group -
Experimental: BI 1291583: Medium dose group -
Experimental: BI 1291583: High dose group -
Placebo comparator: Placebo -
Treatment: Drugs: BI 1291583
BI 1291583
Treatment: Drugs: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to first pulmonary exacerbation up to 48 weeks after first drug administration
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to week 48
Query!
Secondary outcome [1]
0
0
Key secondary: Rate of pulmonary exacerbations (number of events per person-time) up to week 48 after first drug administration
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to week 48
Query!
Secondary outcome [2]
0
0
Absolute change from baseline in Quality of Life Questionnaire - Bronchiectasis (QOLB) respiratory symptoms domain score at week 24 after first drug administration
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
At baseline and at week 24
Query!
Secondary outcome [3]
0
0
Relative change from baseline in neutrophil elastase (NE) activity in sputum at week 12 after first drug administration
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
At baseline and at week 12
Query!
Secondary outcome [4]
0
0
Absolute change from baseline in St. George's Respiratory Questionnaire (SGRQ) Symptoms score at week 24 after first drug administration
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
At baseline and at week 24
Query!
Secondary outcome [5]
0
0
Absolute change from baseline in percent predicted post-bronchodilator forced expiratory volume in one second (FEV1%pred) at week 24 after first drug administration
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
At baseline and at week 24
Query!
Secondary outcome [6]
0
0
Occurrence of an exacerbation by week 24 after first drug administration
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to week 24
Query!
Eligibility
Key inclusion criteria
- Male or female patients: Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the patient information.
Men participating in this clinical trial must use male contraception (condom or sexual abstinence) if their sexual partner is a WOCBP.
* Signed and dated written informed consent prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation.
* Age of patients when signing the informed consent =18 (for Korea: =19) and =85 years.
* Clinical history consistent with bronchiectasis (e.g., cough, chronic sputum production and/or recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by computed tomography (CT) scan. Subjects whose past chest radiographic image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than 5 years.
* History of pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, patients must have had either:
* at least 2 exacerbations, or
* at least 1 exacerbation and a St. George´s Respiratory Questionnaire (SGRQ) Symptoms score of >40 at screening visit 1.
For patients on stable oral or inhaled antibiotics as chronic treatment for bronchiectasis, at least one exacerbation must have occurred since initiation of stable antibiotics.
- Current sputum producers with a history of chronic expectoration who are able to provide a spontaneous (not induced) sputum sample at Screening Visit 1.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Laboratory and medical examination
* Aspartate Aminotransferase (AST) and / or Alanine Aminotransferase (ALT) >3.0 x upper limit of normal (ULN) at Visit 1, or moderate or severe liver disease (defined by Child-Pugh score B or C hepatic impairment).
* Estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula < 30 mL/min at Visit 1.
* An absolute blood neutrophil count <1,000/mm^3 at Visit 1 (equivalent to <1,000 cells/µL or <109 cells/L).
* Any findings in the medical examination and/or laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the patient at risk by participating in the trial.
* Positive serological tests for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection, or known infection status.
Concomitant diagnosis and therapy
* A current diagnosis of:
* Cystic Fibrosis
* Hypogammaglobulinemia
* Common variable immunodeficiency
* a1-antitrypsin deficiency being treated with augmentation therapy
* Allergic bronchopulmonary aspergillosis being treated or requiring treatment
* Tuberculosis or non-tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
* Palmoplantar keratosis; or keratoderma climactericum
* Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
* Psoriasis affecting palms and soles; or body surface area for psoriasis = 10%
* Reactive arthritis (Reiter's syndrome); keratoderma blennorrhagicum
* Pityriasis rubra pilaris
* Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis = 10%
* Active extensive verruca vulgaris, as per investigator's discretion
* Active fungal infection of hand and/or feet not adequately treated, or not responsive to antifungal therapy, as per investigator's discretion.
* Any clinically relevant (at the discretion of the investigator) acute respiratory infection within 4 weeks prior Visit 2, or any other acute infection requiring systemic or inhaled anti-infective therapy within 4 weeks prior Visit 2.
* Any evidence of a concomitant disease, such as Papillon-Lefevre Syndrome, relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal disorders, or patients who are immunocompromised with a higher risk of invasive pneumococcal disease or other invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis), that in the opinion of the investigator, may put the patient at risk by participating in the study.
* Received any live attenuated vaccine within 4 weeks prior to Visit 2.
* Medical conditions associated with periodontal disease (to be evaluated by a periodontist or dentist):
* Any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study (e.g. pulp necrosis).
* Severe periodontal disease defined as with pocket depth measurements = 6 mm on 2 or more teeth.
* Class-3 mobility or Class-3 furcation involvement.
* Scheduled tooth extraction during the study period.
* Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
Further exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/03/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/05/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
322
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Query!
Recruitment hospital [1]
0
0
Macquarie University - North Ryde
Query!
Recruitment hospital [2]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [3]
0
0
Lung Research Queensland - Chermside
Query!
Recruitment hospital [4]
0
0
Mater Research Institute - South Brisbane
Query!
Recruitment hospital [5]
0
0
Institute for Respiratory Health - Nedlands
Query!
Recruitment hospital [6]
0
0
Trialswest - Spearwood
Query!
Recruitment postcode(s) [1]
0
0
2109 - North Ryde
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [4]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [6]
0
0
6153 - Spearwood
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
South Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Gent
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Leuven
Query!
Country [12]
0
0
Bulgaria
Query!
State/province [12]
0
0
Kozloduy
Query!
Country [13]
0
0
Bulgaria
Query!
State/province [13]
0
0
Montana
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Razgrad
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Ruse
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Sofia
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Migration Data
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Quebec
Query!
Country [19]
0
0
Czechia
Query!
State/province [19]
0
0
Kralupy nad Vltavou
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Prague 9
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Hvidovre
Query!
Country [22]
0
0
Denmark
Query!
State/province [22]
0
0
København Ø
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Odense
Query!
Country [24]
0
0
Denmark
Query!
State/province [24]
0
0
Roskilde
Query!
Country [25]
0
0
Denmark
Query!
State/province [25]
0
0
Vejle
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Ålborg
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Amiens
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Montpellier
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Paris
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Rennes
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Berlin
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Essen
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Frankfurt
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Großhansdorf
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Immenhausen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Konstanz
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Lübeck
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
München
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Wiesbaden
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
Ioannina
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Budapest
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Pecs
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Beer Sheva
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Haifa
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Jerusalem
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Tel Aviv
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Palermo
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Pavia
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Rozzano (MI)
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Aichi, Nagoya
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Aomori, Hirosaki
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Chiba, Kamogawa
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Fukuoka, Fukuoka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Ibaraki, Naka-gun
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Kagoshima, Kagoshima
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Mie, Matsusaka
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Niigata, Niigata
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Osaka, Toyonaka
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Saga, Saga
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Tokyo, Kiyose
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Tokyo, Minato-ku
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Cheongju
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Seoul
Query!
Country [64]
0
0
Latvia
Query!
State/province [64]
0
0
Daugavpils
Query!
Country [65]
0
0
Latvia
Query!
State/province [65]
0
0
Jurmala
Query!
Country [66]
0
0
Latvia
Query!
State/province [66]
0
0
Riga
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
Chihuahua
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
Monterrey, Nuevo León
Query!
Country [69]
0
0
Mexico
Query!
State/province [69]
0
0
Monterrey
Query!
Country [70]
0
0
Mexico
Query!
State/province [70]
0
0
Nuevo Leon
Query!
Country [71]
0
0
Mexico
Query!
State/province [71]
0
0
Oaxaca
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Tlalnepantla
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Amsterdam
Query!
Country [74]
0
0
Netherlands
Query!
State/province [74]
0
0
Zutphen
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Bialystok
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Piaseczno
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Swidnik
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Warszawa
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Wroclaw
Query!
Country [80]
0
0
Portugal
Query!
State/province [80]
0
0
Lisboa
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Barcelona
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
L'Hospitalet de Llobregat
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Madrid
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Mérida
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Pozuelo de Alarcón
Query!
Country [86]
0
0
Turkey
Query!
State/province [86]
0
0
Bursa
Query!
Country [87]
0
0
Turkey
Query!
State/province [87]
0
0
Istanbul
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Cambridge
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Dundee, Scotland
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Liverpool
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations).
The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis.
Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day.
Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff.
The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05238675
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/study/NCT05238675
Download to PDF